Concepedia

Author

Patrick Durez

Cliniques Universitaires Saint-LucORCID

Also Known As

DUREZ P, Durez, P, Durez, P., Durez, Patrick, E. L. Nasonov, Laurent Meric de Bellefon, Myles J. Lewis, P DUREZ, P Durez, P. DUREZ

400

Publications

13K

Citations

50

H-Index

75

Concepts

All Affiliations

Cliniques Universitaires Saint-LucUCLouvainKU LeuvenErasmus HospitalStanford University
PD

About

Patrick Durez is an author at Cliniques Universitaires Saint-Luc specializing in medicine, immunology, and rheumatology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

16

24

2.2K

2

Public Health

2

2

36

3

Health Sciences

1

1

26

4

Allergy

1

1

22

5

Athletic Training

1

1

26

Patrick Durez

×

108

Publications

9.6K

Citations

45

H-Index

YearCitations

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

Paul Emery, Ferdinand C. Breedveld, Stephen Hall,

The Lancet

2008

813

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve‐month results of a phase iib, double‐blind, randomized, placebo‐controlled trial

Joel M. Kremer, Maxime Dougados, Paul Emery,

Arthritis & Rheumatism

2005

445

Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase <scp>III</scp>, Double‐Blind, Randomized Controlled Trial

Roy Fleischmann, Aileen L. Pangan, In‐Ho Song,

Arthritis & Rheumatology

2019

410

Role of interleukin‐4 and interleukin‐10 in murine collagen‐induced arthritis. Protective effect of interleukin‐4 and interleukin‐10 treatment on cartilage destruction

Leo A. B. Joosten, Erik Lubberts, Patrick Durez,

Arthritis & Rheumatism

1997

399

Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate‐naive patients with active rheumatoid arthritis: Twenty‐four–week results of a phase III, multicenter, randomized, double‐blind, placebo‐controlled study of golimumab before methotrexate as first‐line therapy for early‐onset rheumatoid arthritis

Paul Emery, Roy Fleischmann, Larry W. Moreland,

Arthritis & Rheumatism

2009

393

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial

Josef S Smolen, Peter Nash, Patrick Durez,

The Lancet

2013

348

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors

René Westhovens, M. Robles, Antônio Carlos Ximenes,

Annals of the Rheumatic Diseases

2009

347

Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double‐blind, placebo‐controlled, dose‐ranging study

Jonathan Kay, Eric L. Matteson, Bhaskar DasGupta,

Arthritis & Rheumatism

2008

295

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

Mark C. Genovese, Patrick Durez, Hanno B. Richards,

Annals of the Rheumatic Diseases

2012

286

Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial

Frances Humby, Patrick Durez, Maya H Buch,

The Lancet

2021

285

Page 1